Leadership. Core Principles. Client Testimonials.

Seasoned Leadership

RegenMed benefits from a leadership team with deep international managerial, financial, technical, clinical, and scientific experience.

C-suite and board positions at numerous private and public companies in the U.S. and abroad.

Development of early stage companies into larger, profitable entities, often with successful exits.

Senior IT positions at major healthcare insurers and providers. Multiple acquisitions and divestitures. Strong network of onshore and offshore engineers and engineering firms.

Many decades in aggregate of patient care at leading academic medical centers. Departmental and medical society leadership.

Oversight of and participation in dozens of clinical trials, and clinical translation projects. Senior positions in major scientific centers.

Clinical / Scientific Advisory Board

Dan A. Grande, Ph.D.

Director of Operations/ Orthopaedic res. at Feinstein Institute

Peter Johnson, M.D.

President and CEO, Cell X Technologies, Inc.

Christian Jorgensen, M.D., Ph.D.

Professor and Director of the Institute for Regenerative Medicine and Biotherapy (IRMB), INSERM U1183, Saint Eloi Hospital, CHRU Montpellier France

John G. Kennedy, M.D., F.R.C.S.

Orthopaedic Surgeon; Chief of Foot and Ankle Division at NYU Langone Health

Bert R. Mandelbaum, M.D.

Co-Chair of Medical Affairs, Cedars-Sinai Kerlan-Jobe Institute, Team Physician, US Soccer National Teams

Claude T. Moorman, III, M.D.

Director, Sports Medicine at Duke University

James R. Urbaniak, M.D.

Professor of Orthopaedic Surgery at Duke University Medical Center

Kenneth R. Zaslav, M.D.

Director, Center for Regenerative Orthopedic Med

Board of Directors and Management

Dr. William J. Futrell

Chairman Emeritus

Michael Tierney

Co-Founder, Chief Executive Officer and Director

Dolph Courchaine

Chief Information Technology Officer

Laura Prey

Director

Core Principles

What Our Clients Say

The field of regenerative medicine remains growing, both in size and in need for evidence-based standards. ROSM has long been a pioneer of non-surgical treatment options, and that leadership will now extend to the generation and dissemination of real-world evidence across a growing number of protocols, products, and patient populations.

RegenMed shared our strategic vision, and with its turnkey platforms and deep regenerative medicine experience, was the natural partner to help us design and expand this broad initiative.

Imran Siddiqui, M.D., Director of Clinical Operations | ROSM

The Circles platform is very user friendly. The system is completely automated so that the reminders come to the patients, who fill in the data, which then comes to us directly for our analysis. We are able to establish a very good percentage of participation amongst our patients.
‍
I want objective numbers I can share with patients. It is also important for me to be able to share my outcomes with my colleagues. Finally, I want to collect these categories of data since we are in a field facing increased regulatory oversight.

Grant Pagdin, M.D. | Pagdin Health

Breakthrough Regenerative Orthopedics is proud to partner with RegenMed to collect real world evidence on treating SI dysfunction and ligamentous laxity. RegenMed has become our go-to partner for clinical data collection based on their commitment to user-friendly, customer-focused data collection solutions for busy clinicians like ourselves.

Timothy Mazzola, M.D. | Breakthrough Regenerative Orthopedics

I am excited to be working with RegenMed in executing the RWE Program. This will help to expand Summus’ clinical and scientific correlations and reach a broader team of providers to collect valuable data.

Dr. Phil Harrington, Internationally Recognized Expert in Laser Therapies

We partnered with RegenMed over a year ago to collect real-world data by using RegenMed’s Circles Program in order to collect data that can be used to provide evidence, more than trends only. 

Our goal is ultimately to have clear cut evidence what optimal preparation methods and protocols are to facilitate physicians in optimizing their treatment strategies, using a variety of highly efficient and reproducible protocols. 

The platform has accommodated our highly specific research objectives, customer engagement and feedback has been overwhelmingly positive, and we have already generated valuable, statistically significant data for up to 1 year, clearly leading us to further refinement of our protocols.

Peter Everts, PhD, FRSM